By Dr Lucy Mkandawire-Valhmu PhD – Staff Writer Contrary to popular opinion, snacking can actually be valuable to health as long as the foods constituting the snack are healthy ones. Consuming Healthy Snacks is key to weight management and to reducing cholesterol, both of which... + continue reading
Keep a Daily Journal and Change Your Life! By Dan Robey "Keeping a journal will absolutely change your life in ways you've never imagined." - Oprah Winfrey Why is it so important to keep a journal? Here are just a few of the benefits a personal journal will provide you: * A journal will remind you... + continue reading
This Week Most Popular
Men's Health News
Nature beats nurture in exam grade differences
In a large UK study of teenage twins, researchers found that differences in exam grades owed more to genes than family environment, schools and teachers. In math, English and science, genes accounted for nearly 60% of the differences, they found.The team from King's College London reported the results of their study, which involved over 11,000 identical and non-identical 16-year-old twins online in a recent edition of PLOS ONE.
Brentuximab vedotin shows extended survival in HL and sALCL
Updated 3-year results for two brentuximab vedotin (Adcetris™) pivotal phase II trials in patients with relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma both showed extended survival for these heavily pre-treated patients. The studies were presented at the 55th American Society of Hematology meeting, held in New Orleans, LA, December 7-10, 2013.
SAGE Therapeutics presents new data identifying highly selective, oral compounds and novel approach for the treatment of chronic epilepsies
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, has announced new data presented at the American Epilepsy Society (AES) Annual Meeting that reveal a novel mechanism and approach for the treatment of status epilepticus (SE) and identify new, orally bioavailable compounds that may lead to improved therapies for chronic epilepsies."Epilepsy is among many disorders of the CNS that have a critical unmet need," said Al Robichaud, Ph.D., chief scientific officer of SAGE.